Finally, the genetic background in which the IDH mutation functions determines whether gliomas will be resistant or sensitive to radiotherapy, because concomitant loss of TP53 and alpha thalassemia/mental retardation syndrome X-linked gene (ATRX) results in a radio-resistant phenotype of IDH-mutated gliomas [40]. The gene discussed is IDH2; the disease is central nervous system cancer.